Vertex Pharmaceuticals

The official channel for Vertex Pharmaceuticals.

[Vertex Pharmaceuticals @VertexPharma]

Today we announced an agreement to acquire @Crinetics. This deal adds to our portfolio of transformative medicines & leverages our strengths in R&D & commercialization to bring more potentially best-in-class medicines to patients with serious diseases. https://t.co/itLnyPRjka

[Vertex Pharmaceuticals @VertexPharma]

A landmark update for children living with #SickleCellDisease or #TransfusionDependentBetaThalassemia: The @US_FDA has approved a label extension for our #CRISPR-based therapy.

Learn more: https://t.co/ivINa0xQwE

[Vertex Pharmaceuticals @VertexPharma]

We presented data on our gene-edited therapy for people with sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Congress and announced regulatory submissions for potential future use in additional patients. Find out more: https://t.co/4sODTw5m91

We’re grateful to the researchers, clinicians, and patients whose contributions help move the science forward.

#EHA2026

[Vertex Pharmaceuticals @VertexPharma]

Extended reimbursement agreement with National Health Insurance Fund in #NorthMacedonia: Since May 20, 2026, eligible people living with #CysticFibrosis ages 2 years and older have broad access to one of our medicines.

[Vertex Pharmaceuticals @VertexPharma]

We are proud to announce that the U.S. FDA has accepted our Biologics License Application (BLA) for our investigational therapy for #IgANephropathy. Learn more: https://t.co/1EYB9Ukl1W

[Vertex Pharmaceuticals @VertexPharma]

First reimbursement agreement in #Chile: Eligible people living with #CysticFibrosis now have reimbursed access to one of our #CysticFibrosis therapies.

[Vertex Pharmaceuticals @VertexPharma]

Major update for the treatment of cystic fibrosis (CF) in the U.S.: The FDA has approved the label extension for our triple combination therapies, expanding availability of these medicines to ~95% of all people with CF in the U.S.
Learn more: https://t.co/3GMdzqJbQ4

[Vertex Pharmaceuticals @VertexPharma]

We’re excited to share positive topline results from the interim analysis of the RAINIER Phase 3 study of our investigational therapy for #IgANephropathy. Learn more: https://t.co/1bgWKtIJiq

[Vertex Pharmaceuticals @VertexPharma]

We’re pleased to share results from the Phase 4 study of our non‑opioid treatment for moderate‑to‑severe acute pain, presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting: https://t.co/TbOj17lNj8

[Vertex Pharmaceuticals @VertexPharma]

Announcing a reimbursement agreement with the Italian Medicines Agency (AIFA) for access to our latest cystic fibrosis (CF) therapy for eligible patients 6 years and older and expanded access to two of our other medicines for eligible patients 2 years old and older.

[Vertex Pharmaceuticals @VertexPharma]

Vertex is committed to the safety and security of all job seekers. If you receive suspicious recruitment messages or believe you have been targeted by a recruitment scam, do not respond or provide any information. Learn how to identify recruitment scams: https://t.co/AMdQ4OjMOx

[Vertex Pharmaceuticals @VertexPharma]

We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Bulgaria. This new agreement has enabled broad access for eligible people living with CF ages 6 years and older since Jan 5, 2026.

[Vertex Pharmaceuticals @VertexPharma]

Extended reimbursement agreement with the Croatian health authorities: Since Dec 30, 2025, eligible children living with #CysticFibrosis ages 1 year and older have had broad access to some of our medicines.

[Vertex Pharmaceuticals @VertexPharma]

We are pleased to share new data from multiple studies of our gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia at the 67th ASH Annual Meeting this weekend. Learn more: https://t.co/LbVnijbX6R #ASH25

[Vertex Pharmaceuticals @VertexPharma]

Extended reimbursement agreement with the health authorities of #Slovakia: eligible people living with #CysticFibrosis ages 2 year and older will now have broad access to one of our medicines.

[Vertex Pharmaceuticals @VertexPharma]

We're excited to share several advancements across our investigational programs for the potential treatment of IgA nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). Learn more: https://t.co/alvB3I1ycf

[Vertex Pharmaceuticals @VertexPharma]

#Breaking: Today Health Canada granted marketing authorization for our fifth cystic fibrosis (CF) medicine.

[Vertex Pharmaceuticals @VertexPharma]

We are proud to announce that our acute pain medicine has been recognized as a 2025 Breakthroughs Innovation Celebration winner by @PremierHA, a leading healthcare improvement company. Learn more: https://t.co/E8TlYTLnD1

[Vertex Pharmaceuticals @VertexPharma]

Today the European Commission approved our fifth cystic fibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

[Vertex Pharmaceuticals @VertexPharma]

We are excited to share that data for our investigational stem cell-derived, fully differentiated islet cell therapy for #Type1Diabetes were published in @NEJM. Learn more: https://t.co/ttKpwaR7vY